{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Neoplasms&page=27", "query": { "condition": "Breast Neoplasms", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 7072, "total_pages": 708, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Neoplasms&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Neoplasms&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T17:25:30.174Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03362060", "title": "PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "PVX-410", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2017-12-12", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-23T17:25:30.174Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03362060" }, { "nct_id": "NCT06917313", "title": "FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Early Stage Breast Cancer (Stage 1-3)" ], "interventions": [ { "name": "Fezolinetant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 92, "start_date": "2025-12-05", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-23T17:25:30.174Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Columbus, Ohio", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06917313" }, { "nct_id": "NCT00022074", "title": "Gabapentin For the Control of Hot Flashes in Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety Disorder", "Breast Cancer", "Depression", "Hot Flashes" ], "interventions": [ { "name": "gabapentin", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Gary Morrow", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "FEMALE", "summary": "Up to 120 Years · Female only" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2015-10-15", "last_synced_at": "2026-10-23T17:25:30.174Z", "location_count": 18, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 15 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022074" }, { "nct_id": "NCT04216576", "title": "A Study of the Use of Text Message Reminders to Take Palbociclib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Paper Drug Diary", "type": "OTHER" }, { "name": "OhMD APP", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2019-12-27", "completion_date": "2026-12-27", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-23T17:25:30.174Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04216576" }, { "nct_id": "NCT06797635", "title": "Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Epirubicin hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 372, "start_date": "2025-03-20", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-23T17:25:30.174Z", "location_count": 8, "location_summary": "Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Billings", "state": "Montana" }, { "city": "Tigard", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06797635" }, { "nct_id": "NCT00016276", "title": "Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiac Toxicity", "Inflammatory Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "dexrazoxane hydrochloride", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 396, "start_date": "2001-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-23T17:25:30.174Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016276" }, { "nct_id": "NCT02639208", "title": "Novel Social Media Intervention For Older Br CA Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer Stage I", "Breast Cancer Stage II", "Breast Cancer Stage III" ], "interventions": [ { "name": "PatientsLikeMe (PLM)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "FEMALE", "summary": "60 Years and older · Female only" }, "enrollment_count": 47, "start_date": "2016-02-08", "completion_date": "2021-08-06", "has_results": false, "last_update_posted_date": "2021-08-20", "last_synced_at": "2026-10-23T17:25:30.174Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02639208" }, { "nct_id": "NCT03326713", "title": "Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "Telephone Counseling & Navigation (TCN)", "type": "BEHAVIORAL" }, { "name": "Mailed Targeted Print (TP)", "type": "BEHAVIORAL" }, { "name": "Usual Care (UC)", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 668, "start_date": "2017-11-02", "completion_date": "2022-06-02", "has_results": true, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-23T17:25:30.174Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03326713" }, { "nct_id": "NCT05514717", "title": "A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2-positive Non-Small Cell Lung Cancer", "HER2-positive Colorectal Cancer", "HER2-positive Tumors", "HER2 Low Breast Cancer" ], "interventions": [ { "name": "XMT-2056", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Day One Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2023-01-24", "completion_date": "2026-05-22", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-23T17:25:30.174Z", "location_count": 14, "location_summary": "Los Angeles, California • Stanford, California • Celebration, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Celebration", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05514717" }, { "nct_id": "NCT03847168", "title": "KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Gastric/Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "KN026", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jiangsu Alphamab Biopharmaceuticals Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-06-18", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2021-11-17", "last_synced_at": "2026-10-23T17:25:30.174Z", "location_count": 1, "location_summary": "Greenville, South Carolina", "locations": [ { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03847168" } ] }